The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes

Experimental and Clinical Immunogenetics

Volumn 15, Issue 1, 1998, Pages 19-32

  Kirkin, Alexei F ^a   Dzhandzhugazyan, Karine ^a   Zeuthen, Jesper ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Cytotoxic T lymphocytes; Immunogenicity; Immunotherapy; Melanoma associated antigens

Indexed keywords

DIFFERENTIATION ANTIGEN; HLA ANTIGEN CLASS 1; PROTEASOME; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; CYTOTOXIC T LYMPHOCYTE; GERM CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; TESTIS;

EID: 0031968122     PISSN: 02549670     EISSN: None     Source Type: Journal    
DOI: 10.1159/000019050     Document Type: Review

References (73)

1. Barker CF, Billingham RE: Immunologically privileged sites. Adv Immunol 1977;25:1-54.
2. Adema GJ, de Boer AJ, Van't Hullenaar R, Denijn M, Ruiter DJ, Vogel AM, Figdor CG: Melanocytic lineage-specific antigens recognized by monoclonal antibodies NKI-beteb. HMB-50 and HMB-45. Am J Pathol 1993;143:1579-1585.
3. Chambost, Brasseur F, Coulie P, De Plaen E, Stoppa AM, Baume D, Mannoni P, Boon T, Maraninchi D, Olive D: A tumour-associated antigen expression in human haematological malignancies. Br J Haematol 1993;84:524-526.
4. Shichijo S, Tsunosue R, Masuoka K, Naton H, Tamai M, Miyajima J, Sagawa K, Ito K: Expression of the MAGE gene family in human lymphocytic leukemia. Cancer Immunol Immunother 1995;41:95-103.
5. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37-44.
6. Robbins PF, El-Gamil M, Kawakami Y, Rosenberg SA: Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994;54:3124-3126.
7. Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995;55:4972-4979.
8. Takahashi K, Shichijo S, Noguchi M, Hirohata M, Itoh K: Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res 1995;55:3478-3482.
9. INK4A characterize the major types of hematological malignancies. Cancer Res 1997;57: 837-841.
10. Bartkova J, Lukas J, Guldberg P, Aisner J, Kirkin AF, Zeuthen J, Bartek J: The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996;56:5475-5483.
11. Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde KH, Boon T: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994;24:759-764.
12. van der Bruggen P, Szikora JP, Boël P, Wildmann C, Somville M, Sensi M, Boon T: Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol 1994;24:2134-2140.
13. Brichard VG, Herman J, Van Pel A, Wildmann C, Gaugler B, Wölfel T, Boon T, Lethé B: A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 1996;26:224-230.
14. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG: Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995;25:340-347.
15. van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P, de Smet C, Traversari C, Townsend A, Boon T: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3, Eur J Immunol 1994;24:3038-3043.
16. van Elsas A, van der Burg SH, Van der Minne CE, Borghi M, Mourer JS, Melief CJM, Schrier PI: Peptidepulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. Eur J Immunol 1996;26: 1683-1689.
17. Yamashita N, Ishibashi H, Hayashida K, Kudo J, Takenaka K, Itoh K, Niho Y: High frequency of the MAGE-1 gene expression in hepatocellular carcinoma. Hepatology 1996;24:1437-1440.
18. Niedermann G, Butz S, Ihlenfeldt HG, Grimm R, Lucchiari M, Hoschützky H, Jung G, Maier B, Eichmann K: Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 1995;2: 289-299.
19. Boël P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, van der Bruggen P: BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-175.
20. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997; 6:199-208.
21. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, de Smet C, Brasseur F, van der Bruggen P, Lethé B, Lurquin C, Brasseur R, Chomez P, De Backer O, Cavenee W, Boon T: Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994;40:360-369.
22. Herman J, van der Bruggen P, Luescher IF, Mandruzzato S, Romero P, Thonnard J, Fleischhauer K, Boon T, Coulie PG: A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics 1996;43:377-383.
23. Kawakami Y, Rosenberg SA: T-cell recognition of self peptides as tumor rejection antigens. Immunol Res 1996;15:179-190.
24. Van Pel A, van der Bruggen P, Coulie PG, Brichard VG, Lethé B, Van den Eynde B, Uyttenhove C, Renauld JC, Boon T: Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 1995;145:229-250.
25. Brasseur F, Rimoldi D, Liénard D, Lethé B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y, Vacca A, Conese M, Lahaye T, Degiovanni G, Deraemaecker R, Beauduin M, Sastre X, Salamon E, Dréno B, Jäger E, Knuth A, Chevreau C, Suciu S, Lachapelle JM, Pouillart P, Parmiani G, Lejeune F, Cerottini JC, Boon T, Marchand M: Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995;63:375-380.
26. Eura M, Ogi K, Chikamatsu K, Lee KD, Nakano K, Masuyama K, Itoh K, Ishikawa T: Expression of the MAGE gene family in human head-and-neck squamous-cell carcinomas. Int J Cancer 1995;64:304-308.
27. Spagnoli GC, Schaefer C, Willimann TE, Kocher T, Amoroso A, Juretic A, Zuber M, Luscher U, Harder F, Heberer M: Peptide-specific CTL in tumor-infiltrating lymphocytes from metastatic melanomas expressing MART-I/Metan-A, gp100 and Tyrosinase genes: A study in an unselected group of HLA-A2.1-positive patients. Int J Cancer 1995;64:309-315.
28. Marchand M, Weynams P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon JL, Laurent C, Naeyaert JM, Plagne R, Deraemaeker R, Knuth A, Jäger E, Brasseur F, Herman J, Coulie PG, Boon T: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995;63:883-885.
29. Ohta M, Berd D, Shimizu M, Nagai H, Cotticelli M-G, Mastrangelo M, Shields JA, Shields CL, Croce CM, Huebner K: Deletion mapping of chromosome region 9p21-022 surrounding the CDKN2 locus in melanoma, Int J Cancer 1997;65:762-767.
30. Patard JJ, Brasseur F, Gil-Diez S, Radvanyi F, Marchand M, Francois P, Abi-Aad A, Van Cangh P, Abbou CC, Chopin D, Boon T: Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer 1995;64:60-64.
31. Mulcahy KA, Rimoldi D, Brasseur F, Rodgers S, Liénard D, Marchand M, Rennie IG, Murray AK, McIntyre CA, Platts KE, Leyvraz S, Boon T, Rees RC: Infrequent expression of the MAGE gene family in uveal melanomas. Int J Cancer 1996;66: 738-742.
32. Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM, Lotze M, Robertson CN, Seipp CA, Simon P, Simpson CG, Rosenberg SA: Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin 2. J Clin Oncol 1988;6:839-853.
33. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-1457.
34. Nonacs R, Humborg C, Tam JP, Steinman RM: Mechanism of mouse spleen dendritic cell function in the generation of influenza-specific. cytolytic T lymphocytes. J Exp Med 1992;176:519-529.
35. Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzochi A, Squarcina P, Herlyn M, Parmiani G: Melanoma cells and normal melanocytes share antigens by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993;177:989-998.
36. Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethé B, Coulie P, Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-495.
37. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA: Identification of the immunodominant peptides of the MART-I human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-352.
38. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethé B, Brasseur F, Boon T: Human gene Mage-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179:921-930.
39. Bakker ABH, Schreurs MWJ, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG: Melanocyte lineage-specific antigen Gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994;179:1005-1009.
40. Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, Renauld JC, Boon T: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
41. Bouchard B, Fuller BB, Vijayasardhi S, Houghton AN: Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J Exp Med 1989;169:2029-2042.
42. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182: 689-698.
43. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995; 181:799-804.
44. Skipper JCA, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wötfel T, Slingluff CL Jr, Boon T, Hut DF, Engelbard VH: An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996;183:527-534.
45. Dick LR, Aldrich C, Jameson SC, Moomaw CR, Pramanick BC, Doyle CK, DeMartino GN, Bevan MJ, Forman JM, Slaughter CA: Proteolytic processing of ovalbumin and β-galactosidase by the proteasome to yield antigenic peptides. J Immunol 1994;152:3884-3894.
46. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli YR, Appella E, Rosenberg SA: Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-2265.
47. Stevens EJ, Jacknin L, Robbins PF, Kawakami Y, El-Gamil M, Rosenberg SA, Yanneili JR: Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines: Fine specificity and MART-1 melanoma antigen recognition. J Immunol 1995;154:762-771.
48. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang XQ, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-3968.
49. Kang XQ, Kawakami Y, El-Gamil M, Wang RF, Sakaguchi K, Yannelli JR, Appella E, Rosenberg SA, Robbins PF: Identification of a tyrosinase epitope recognized by HLA-A24-restricted. tumor-infiltrating lymphocytes. J Immunol 1995;155: 1343-1348.
50. Robbins PF, El-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA: Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995;154:5944-5950.
51. Anichini A, Mortanni R, Maccalli C, Squarcina P, Fleischhauer K, Mascheroni L, Parmiani G: Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2. 1-restricted immune repertoire to melanoma. J Immunol 1996;156:208-217.
52. Tomita Y, Kimura M, Tanikawa T, Nishiyama T, Morishita H, Takeda M, Fujiwara M, Sato S: Immunohistochemical detection of intracellular adhesion molecule-1 (ICAM-1) and major histocompatibility complex class I antigens in seminoma. J Urol 1993;149:659-663.
53. Uetsuki T, Takagi K, Sugiura H, Yoshikawa K: Structure and expression of the mouse necdin gene: Identification of a postmitotic neuronrestrictive core promoter. J Biol Chem 1996;271:918-924.
54. Castelli C, Storkus WJ, Maeurer MJ, Martin DM, Huang EC, Pramanik BN, Nagabhushan TL, Parmiani G, Lotze MT: Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8(+) cytotoxic T lymphocytes. J Exp Med 1995;181:363-368.
55. Ribbons PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA: A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-1192.
56. Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethé B, Jotereau F, Boon T: A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med 1996;183:1173-1183.
57. Wang RF, Parkhursl MR, Kawakami Y, Robbins PF, Rosenberg SA: Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 1996;183:1131-1140.
58. Wang RF, Appella E, Kawakami Y, Kang XQ, Rosenberg SA: Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996;184: 2207-2216.
59. Skipper JCA, Kittlesen DJ, Hendrickson RC, Deacon DD, Harthun NL, Wagner SN, Hunt DF, Engelhard VH, Slingluff CL: Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J Immunol 1996; 157:5027-5033.
60. Robbins PF, El-Gamil M, Li YF, Fitzgerald EB, Kawakami Y, Rosenberg SA: The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J Immunol 1997;159:303-308.
61. Katano M, Nakamura M, Morisaki T, Fujimoto K: Melanoma antigen-encoding gene-1 expression in invasive gastric carcinoma: Correlation with stage of disease. J Surg Oncol 1997;64:195-201.
62. Garnier J, Gibrat JF, Robson B: GOR method for predicting protein secondary structure from amino acid sequence. Methods Enzymol 1996;266:540-553.
63. Goldberg AL, Rock KL: Proteolysis, proteasomes and antigen presentation. Nature 1992;357:375-379.
64. Wenzel T, Baumeister W: Conformational constrains in protein degradation by the 20S proteasome. Nat Struct Biol 1997;2:199-204.
65. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-3519.
66. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-6462.
67. Walker KK, Levine AJ: Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA 1996;93:15335-15340.
68. Coulie PG, Lehmann F, Lethé B, Herman J, Lurquin C, Andrawiss M, Boon T: A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995;92: 7976-7980.
69. Olsen AC, Fossum B, Kirkin AF, Zeuthen J, Gaudernack G: A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses. Scand J Immunol 1995;41:357-364.
70. Rogers S, Wells R, Rechsteiner M: Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis. Science 1986; 234:364-368.
71. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T on a human melanoma. Science 1991;254:1643-1647.
72. Cox AL, Skipper J, Chen Y, Headerson RA Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-719.
73. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-1284.